Natural Beauty Bio-Technology (0157) AI Stock Analysis

• Market Cap: HK$1.04B
• Dividend Yield: N/A
• Average Volume (3M): 270.33K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.11
• Revenue Growth: 5.25%
• EPS Growth: -581.58%
• Country: HK
• Employees: 542
• Sector: Consumer Defensive
• Sector Strength: 55
• Industry: Household & Personal Products
• EPS (TTM): -0.05
• Shares Outstanding: 2,002,101,000
• 10 Day Avg. Volume: 244,000
• 30 Day Avg. Volume: 270,333
• PEG Ratio: 0.06
• Price to Book (P/B): 2.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -19.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$0.47
• Price Target Upside: -12.78% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: HK$0.50 ▼(-7.41%Downside)

The overall stock score reflects significant financial performance challenges, offset slightly by positive technical momentum. Negative valuation due to lack of profitability and no dividend yield also weigh heavily on the score.

Natural Beauty Bio-Technology Business Overview & Revenue Model

Company Description

Natural Beauty Bio-Technology (0157) is a company that operates within the cosmetics and skincare industry, focusing on the development, manufacturing, and distribution of beauty and skincare products. The company leverages advanced biotechnology to create innovative and natural products catering to the personal care needs of consumers. Its core offerings include a range of skincare solutions, cosmetics, and health supplements designed to enhance beauty and well-being.

How the Company Makes Money

Natural Beauty Bio-Technology generates revenue primarily through the sale of its beauty and skincare products. The company utilizes a multi-channel distribution strategy, including retail partnerships, e-commerce platforms, and direct-to-consumer sales. Additionally, it may engage in strategic partnerships with other companies in the beauty and health sectors to expand its market reach and enhance product offerings. Revenue is driven by consumer demand for high-quality, natural, and effective skincare solutions, and the company invests in research and development to continually innovate and introduce new products to the market.

Natural Beauty Bio-Technology Financial Statement Overview

Summary

The company is facing significant financial challenges with declining revenue and profitability. Increased leverage and negative cash flow trends indicate financial instability.

Income Statement

The company has experienced a decline in revenue from 2021 to 2024, indicating negative growth. Gross profit margins have decreased while net profit margins are negative, showing a lack of profitability. EBIT and EBITDA margins have worsened significantly, marking a challenging operating environment.

Balance Sheet

The debt-to-equity ratio has increased over the years, reflecting rising leverage, yet it remains manageable. The equity ratio has decreased slightly, suggesting a decline in asset financing through equity. Return on equity is negative due to net losses, which is a concern for profitability.

Cash Flow

The company has seen a negative trend in free cash flow, with significant declines from 2021 to 2024. The operating cash flow to net income ratio is negative, indicating operational challenges. Free cash flow to net income ratio also reflects cash flow difficulties, hindering financial flexibility.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	353.65M	336.01M	335.88M	487.81M	410.67M
Gross Profit	202.33M	200.34M	165.33M	281.80M	217.22M
EBITDA	-65.50M	22.91M	15.09M	85.23M	41.57M
Net Income	-103.61M	-15.11M	-30.47M	35.26M	7.76M
Balance Sheet
Total Assets	772.93M	882.58M	883.53M	937.16M	840.77M
Cash, Cash Equivalents and Short-Term Investments	116.51M	166.81M	168.61M	197.08M	165.61M
Total Debt	212.13M	186.29M	143.48M	129.07M	75.02M
Total Liabilities	325.34M	308.06M	286.07M	279.24M	229.54M
Stockholders Equity	447.59M	574.52M	597.46M	657.92M	611.23M
Cash Flow
Free Cash Flow	-54.96M	-47.39M	-35.98M	4.67M	-43.77M
Operating Cash Flow	-13.75M	21.72M	8.33M	42.78M	30.09M
Investing Cash Flow	-40.17M	-67.61M	-43.98M	-31.21M	-50.63M
Financing Cash Flow	15.34M	42.63M	18.10M	14.31M	29.85M

Natural Beauty Bio-Technology Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.54
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0157, the sentiment is Neutral. The current price of 0.54 is below the 20-day moving average (MA) of 0.55, above the 50-day MA of 0.53, and above the 200-day MA of 0.50, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 43.59 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0157.

Natural Beauty Bio-Technology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2145	77 Outperform	HK$31.01B	35.31	37.28%	2.18%	59.83%	68.29%
1925	68 Neutral	HK$502.25M	3.91	24.41%	5.38%	22.46%	91.73%
3332	64 Neutral	HK$842.47M	12.12	8.96%	―	30.72%	-35.61%
2177	61 Neutral	HK$461.19M	11.23	5.25%	5.82%	-23.89%	―
Sector *	61 Neutral	HK$21.08B	12.39	0.81%	4.52%	2.72%	-47.45%
0157	48 Neutral	HK$1.04B	―	-20.26%	―	5.25%	-581.58%
6993	48 Neutral	HK$24.21B	―	-7.87%	2.49%	16.82%	-348.71%

Natural Beauty Bio-Technology Corporate Events

Natural Beauty Bio-Technology Schedules Board Meeting for Interim Results

Natural Beauty Bio-Technology Limited has announced a board meeting scheduled for August 5, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the payment of an interim dividend, which could impact shareholder returns and market perception of the company’s financial health.

Natural Beauty Bio-Technology Reports Strong Revenue Growth and Profit Turnaround

Natural Beauty Bio-Technology Limited announced a significant financial turnaround for the first half of 2025, with expected revenues of approximately HK$270 million, marking a 72% increase from the previous year. This growth is attributed to the company’s strategic expansion in the Mainland China market and improved operational efficiencies, leading to a projected net profit of HK$10 million, compared to a net loss in the same period last year.

Natural Beauty Bio-Technology Unanimously Passes AGM Resolutions

Natural Beauty Bio-Technology Limited held its Annual General Meeting on May 22, 2025, where all proposed resolutions were unanimously passed. These resolutions included the approval of financial statements, re-election of directors, and granting mandates for share repurchase and issuance, indicating strong shareholder support and strategic flexibility for the company.